Papers

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up

^a Section of Old Age Psychiatry, University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, ^b University Department of Psychiatry, Warneford Hospital, Oxford, OX3 7JX

Correspondence to: Dr McShane

Objective: To investigate the contribution of neuroleptic drugs to cognitive decline in dementia.
Design: Two year prospective, longitudinal study consisting of interviews every four months, with necropsy follow up.
Setting: Community settings in Oxfordshire.
Subjects: 71 subjects with dementia, initially living at home with informant.
Main outcome measures: Cognitive function (score from expanded minimental state examination); behavioural problems (physical aggression, hallucinations, persecutory ideas, and disturbance of diurnal rhythm); and postmortem neuropathological assessment (cortical Lewy body pathology).
Results: The mean (SE) decline in cognitive score in the 16 patients who took neuroleptics was twice that in the patients who did not (20.7 (2.9) v 9.3 (1.3), P=0.002). An increased rate of decline was also associated with aggression, disturbed diurnal rhythm, and persecutory ideas. However, only use of neuroleptics and severity of persecutory ideas were independently associated with more rapid cognitive decline when all other variables were adjusted for. The start of neuroleptic treatment coincided with more rapid cognitive decline: median rate of decline was 5 (interquartile range 8.5) points per year before treatment and 11 (12) points per year after treatment (P=0.02). Cortical Lewy body pathology did not account for association between neuroleptic use and more rapid decline.
Conclusions: Neuroleptic drugs that are sometimes used to treat behavioural complications of dementia may worsen already poor cognitive function. Randomised controlled trials are needed to confirm a causal relation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

Clive Ballard, Marisa Margallo-Lana, Edmund Juszczak, Simon Douglas, Alan Swann, Alan Thomas, John O'Brien, Anna Everratt, Stuart Sadler, Clare Maddison, Lesley Lee, Carol Bannister, Ruth Elvish, and Robin Jacoby
BMJ 2005 330: 874. [Abstract] [Full Text] [PDF]

Do neuroleptic drugs hasten cognitive decline in dementia?

C Holmes, O Fortenza, J Powell, S Lovestone, Robert Tobiansky, Martin Blanchard, P W Bentham, S E Goh, E M Gregg, P Madeley, A R A Patel, A P Taylor, Rupert McShane, Tony Hope, Robin Jacoby, Janet Keene, and Christopher Fairburn
BMJ 1997 314: 1411. [Extract] [Full Text]

This article has been cited by other articles:

• Jalbert, J. J., Daiello, L. A., Lapane, K. L. (2008). Dementia of the Alzheimer Type. Epidemiol Rev 30: 15-34 [Abstract] [Full text]  
• Wood-Mitchell, A., James, I. A., Waterworth, A., Swann, A., Ballard, C. (2008). Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age Ageing 37: 547-552 [Abstract] [Full text]  
• Brooks, J. O., Hoblyn, J. C. (2007). Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults. J Geriatr Psychiatry Neurol 20: 199-214 [Abstract]  
• (2007). How safe are antipsychotics in dementia?. DTB 45: 81-85 [Abstract] [Full text]  
• Kales, H. C., Valenstein, M., Kim, H. M., McCarthy, J. F., Ganoczy, D., Cunningham, F., Blow, F. C. (2007). Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications. Am. J. Psychiatry 164: 1568-1576 [Abstract] [Full text]  
• Alldred, D. P., Petty, D. R., Bowie, P., Zermansky, A. G., Raynor, D. K. (2007). Antipsychotic prescribing patterns in care homes and relationship with dementia. Psychiatr. Bull. 31: 329-332 [Abstract] [Full text]  
• Livingston, G, Walker, A E, Katona, C L E, Cooper, C (2007). Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. J. Neurol. Neurosurg. Psychiatry 78: 25-29 [Abstract] [Full text]  
• Aupperle, P. (2006). Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics. AM J ALZHEIMERS DIS OTHER DEMEN 21: 101-108 [Abstract]  
• Schneider, L. S., Dagerman, K. S., Insel, P. (2005). Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials. JAMA 294: 1934-1943 [Abstract] [Full text]  
• Karim, S., Byrne, E. J. (2005). Treatment of psychosis in elderly people. Adv. Psychiatr. Treat. 11: 286-296 [Abstract] [Full text]  
• Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., Lee, L., Bannister, C., Elvish, R., Jacoby, R. (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330: 874- [Abstract] [Full text]  
• Aarsland, D., Andersen, K., Larsen, J. P., Perry, R., Wentzel-Larsen, T., Lolk, A., Kragh-Sorensen, P. (2004). The Rate of Cognitive Decline in Parkinson Disease. Arch Neurol 61: 1906-1911 [Abstract] [Full text]  
• (2003). Drugs for disruptive features in dementia. DTB 41: 1-4 [Abstract] [Full text]  
• Burns, A., Byrne, J., Ballard, C., Holmes, C. (2002). Sensory stimulation in dementia. BMJ 325: 1312-1313 [Full text]  
• Greicius, M D, Geschwind, M D, Miller, B L (2002). Presenile dementia syndromes: an update on taxonomy and diagnosis. J. Neurol. Neurosurg. Psychiatry 72: 691-700 [Abstract] [Full text]  
• Furniss, L. (2002). Use of medicines in nursing homes for older people. Adv. Psychiatr. Treat. 8: 198-204 [Full text]  
• Sweet, R. A., Kamboh, M. I., Wisniewski, S. R., Lopez, O. L., Klunk, W. E., Kaufer, D. I., DeKosky, S. T. (2002). Apolipoprotein E and Alpha-1-Antichymotrypsin Genotypes Do Not Predict Time to Psychosis in Alzheimer's Disease. J Geriatr Psychiatry Neurol 15: 24-30 [Abstract]  
• Talerico, K. A., Evans, L. K., Strumpf, N. E. (2002). Mental Health Correlates of Aggression in Nursing Home Residents With Dementia. Gerontologist 42: 169-177 [Abstract] [Full text]  
• Sweet, R. A., Nimgaonkar, V. L., Devlin, B., Lopez, O. L., DeKosky, S. T. (2002). Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 58: 907-911 [Abstract] [Full text]  
• Lopez, O L, Becker, J T, Wisniewski, S, Saxton, J, Kaufer, D I, DeKosky, S T (2002). Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 72: 310-314 [Abstract] [Full text]  
• Bouman, W. P., Pinner, G. (2002). Use of atypical antipsychotic drugs in old age psychiatry. Adv. Psychiatr. Treat. 8: 49-58 [Full text]  
• Ballard, C., O'Brien, J. (1999). Treating behavioural and psychological signs in Alzheimer's disease. BMJ 319: 138-139 [Full text]  
• McKenzie, D. A., Mullooly, J. P., McFarland, B. H., Semradek, J. A., McCamant, L. E. (1999). Changes in Antipsychotic Drug Use Following Shifts in Policy: A Multilevel Analysis. Research on Aging 21: 304-337 [Abstract]  
• Devanand, D.P., Marder, K., Michaels, K. S., Sackeim, H. A., Bell, K., Sullivan, M. A., Cooper, T. B., Pelton, G. H., Mayeux, R. (1998). A Randomized, Placebo-Controlled Dose-Comparison Trial of Haloperidol for Psychosis and Disruptive Behaviors in Alzheimer's Disease. Am. J. Psychiatry 155: 1512-1520 [Abstract] [Full text]  
• Callaway, J. T. (1998). Psychopharmacological Treatment of Dementia. Research on Social Work Practice 8: 452-474 [Abstract]  
• Holmes, C, Fortenza, O, Powell, J, Lovestone, S, Tobiansky, R., Blanchard, M., Bentham, P W, Goh, S E, Gregg, E M, Madeley, P, Patel, A R A, Taylor, A P, McShane, R., Hope, T., Jacoby, R., Keene, J., Fairburn, C. (1997). Do neuroleptic drugs hasten cognitive decline in dementia?. BMJ 314: 1411-1411 [Full text]  
• (1997). CAN NEUROLEPTIC DRUGS SPEED COGNITIVE DECLINE IN DEMENTIA?. JWatch General 1997: 4-4 [Full text]